How much does a box of lapatinib cost and how cost-effective it is?

Lapatinib(Lapatinib) is an oral small molecule tyrosine kinase inhibitor mainly used to treat patients with HER2-positive breast cancer. The drug achieves anti-tumor effects by simultaneously inhibiting the two signaling pathways of HER2 and EGFR, blocking the proliferation signaling of tumor cells. Lapatinib is particularly suitable for patients who have developed resistance to anti-HER2 monoclonal antibodies such as trastuzumab, and especially shows great potential in HER2-positive breast cancer with brain metastases. Compared with macromolecular antibody drugs, lapatinib has a certain ability to penetrate the blood-brain barrier due to its small molecule structure, so it has obvious advantages in controlling central nervous system lesions.

In China, the original drug lapatinib is already on the market under the trade name Telisa. The common specifications are 0.25g (i.e. 250mg) * 70 tablets, and the price per box is approximately RMB 5,000 to RMB 6,000. At present, this drug has not been included in the national medical insurance catalog, so the burden is relatively heavy for some patients with limited financial conditions. However, in some areas, charitable assistance projects may provide a certain percentage of drug subsidies or exemptions.

In addition to the original drugs in the domestic market, overseas markets also offer a variety of more competitively priced options. For example, Turkey's original lapatinib drug is more affordable due to exchange rate and policy reasons, generally ranging from RMB 2,000 to RMB 3,000 per box. Even more attractive are generic drug products from countries such as India and Bangladesh. These generic drugs are similar to the original drugs in terms of drug ingredients and production quality, and have passed multi-country certification processes, so their safety and efficacy are guaranteed. The Indian and Bangladeshi generic versions generally sell for 600 to 1,000 yuan per box, which has become an important way for many patients to control treatment costs.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html